Top Markets
#1 Black Phoenix Black Phoenix +829.59%
#2 pipedog pipedog +41.28%
#3 PondCoin PondCoin +35.42%
#4 Bless Bless +35.40%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.00%
#7 Beam Beam +24.62%
#8 Seeker Seeker +21.01%
#9 Magma Finance Magma Finance +20.64%
#10 YFSX YFSX +16.15%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rank in Stocks #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Share Price
$64.97
Last synced: 2024-05-20
Market Cap
$1.97B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alpine Immune Sciences, Inc. (ALPN)

Category

Healthcare
P/B ratio for Alpine Immune Sciences, Inc. (ALPN)
P/B ratio as of August 2026 TTM: 9.91
According to Alpine Immune Sciences, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 9.91. At the end of 2022 the company had a P/B ratio of 1.37.
P/B ratio history for Alpine Immune Sciences, Inc. from 2012 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 9.91 240.41%
2023 2.91 112.16%
2022 1.37 -53.07%
2021 2.92 -30.87%
2020 4.22 76.50%
2019 2.39 109.27%
2018 1.14 24.25%
2017 0.92 46.95%
2016 0.63 -27.94%
2015 0.87 -110.05%
2014 -8.64 479.51%
2013 -1.49 0.00%
2012 0.00 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -35.98%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -36.99%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -74.71%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -62.56%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH